Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency...

Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4...

The U.S. Securities and Exchange Commission (SEC) declared today that the registration statement (form of prospectus) filed by Alvotech on August 21, 2024 has now taken effect.

On Tuesday August 27, 2024, Alvotech filed a letter with the U.S. Securities and Exchange Commission (SEC), pertaining to its August 21, 2024, filing of a preliminary prospectus, or “registration statement”. In this letter, Alvotech requests that the SEC takes appropriate actions for the registratio

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd...

On Wednesday August 21, 2024, Alvotech filed a preliminary prospectus on form F-3 with the U.S. Securities and Exchange Commission (SEC). Alvotech filed this preliminary prospectus with the SEC to fulfill contractual obligations with an existing shareholder, Morgan Stanley & Co. (the „shareholder“).

Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190%...

The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...